视网膜退行性疾病替代与保护性细胞治疗策略
本文综述了针对年龄相关性黄斑变性(AMD)和视网膜色素变性(RP)等视网膜退行性疾病的细胞治疗策略,重点讨论替代疗法(利用细胞来源的视网膜色素上皮细胞替代受损宿主细胞)和保护疗法(利用支持细胞通过神经营养机制维持视功能与光感受器)。多项临床试验正在测试这两类细胞疗法的安全性,但疗效指标仍需进一步评估,移植物免疫反应、寿命和功能等问题有待未来试验解决。
要点
- 替代疗法利用细胞来源的RPE细胞替代丢失或有缺陷的宿主RPE细胞,形态和功能与天然RPE相似。
- 保护疗法利用支持细胞通过神经营养机制部分维持视功能和光感受器,目标是阻止或延缓疾病进展。
- 多项临床试验正在测试替代和保护细胞疗法的安全性,但疗效指标仍需进一步评估。
核心结论
- 细胞治疗为视网膜退行性疾病提供了替代和保护两种策略,多项临床试验正在测试安全性,但疗效指标仍需进一步评估。
- 移植物免疫相关反应、寿命和功能等主要关切需在 future trials 中解决。
研究设计与样本
- 本文为综述,总结细胞治疗在视网膜退行性疾病中的临床前和临床研究现状,聚焦替代和保护策略及相关障碍。
主要发现
- 替代疗法利用细胞来源的RPE细胞替代丢失或有缺陷的宿主RPE细胞,这些细胞形态和功能与天然RPE细胞相似,可能替代RPE在体内的职责。
- 保护疗法利用支持细胞通过神经营养机制部分帮助维持视功能和光感受器,目标是阻止或延缓疾病进展并维持剩余视功能。
- 多项临床试验正在测试替代和保护细胞疗法在患者中的安全性,但疗效指标仍需进一步评估。
临床怎么用
- 原文未据此给出推荐。
局限性
- 移植物免疫相关反应、寿命和功能等主要关切需在 future trials 中解决。
- 疗效指标仍需进一步评估。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Cell-based therapeutics offer diverse options for treating retinal degenerative diseases, such as age-related macular degeneration (AMD) and retinitis pigmentosa (RP). AMD is characterized by both genetic and environmental risks factors, whereas RP is mainly a monogenic disorder. Though treatments exist for some patients with neovascular AMD, a majority of retinal degenerative patients have no effective therapeutics, thus indicating a need for universal therapies to target diverse patient populations. Two main cell-based mechanistic approaches are being tested in clinical trials. Replacement therapies utilize cell-derived retinal pigment epithelial (RPE) cells to supplant lost or defective host RPE cells. These cells are similar in morphology and function to native RPE cells and can potentially supplant the responsibilities of RPE in vivo. Preservation therapies utilize supportive cells to aid in visual function and photoreceptor preservation partially by neurotrophic mechanisms. The goal of preservation strategies is to halt or slow the progression of disease and maintain remaining visual function. A number of clinical trials are testing the safety of replacement and preservation cell therapies in patients; however, measures of efficacy will need to be further evaluated. In addition, a number of prevailing concerns with regards to the immune-related response, longevity, and functionality of the grafted cells will need to be addressed in future trials. This review will summarize the current status of cell-based preclinical and clinical studies with a focus on replacement and preservation strategies and the obstacles that remain regarding these types of treatments.
引用
- Jones MK, Lu B, Girman S, et al. Cell-based therapeutic strategies for replacement and preservation in retinal degenerative diseases. Prog Retin Eye Res. 2017. PMID: 28111323. doi:10.1016/j.preteyeres.2017.01.004
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。